The CAR T-Cell Therapy Market To Leverage The Digital Disruption Wave

 According to a recent study by Persistence Market Research, the global CAR T-cell therapy market is anticipated to experience high growth over the coming years. The market is expected to grow from US$ 1.2 Bn in 2020 to over US$ 2.8 Bn by 2031, which reflects a CAGR of around 5.6% for the next ten years.

Key players in the CAR T-cell therapy space are focusing on acquisitions and collaborations with other players of the market to strengthen their position by offering a wide range of products.

  • For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a privately held company of biotherapeutics that discovers and develops cell-based therapies. This acquisition benefits Gilead through gaining novel technology platforms that will its boost R&D efforts in cellular therapy.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/28264

Also, increasing number of clinical trials in the field of life sciences and CAR T-cells will benefit manufacturers and researchers in developing innovative cancer therapy. With a large extent of studies taking place around CAR T-cell therapy, it is anticipated to enhance product availability in the market over the coming years.

  • For instance, the experiment on AntiCD19 Chimeric Antigen Receptor T Cells for the treatment of relapsed or refractory Non-Hodgkin lymphoma by Benjamin Tomlinson is undergoing and is currently in phase I clinical trial.
  • Another study by Janssen Research & Development, LLC of a chimeric antigen receptor T Cell (CAR-T) therapy for myeloma is in phase 2 clinical trial.
  • Furthermore, a study on the safety and efficacy of ALLO-605 in patients with relapsed/refractory multiple myeloma by Allogene Therapeutics is currently in phase 2.

All these factors will drive demand for CAR T-cell therapy during the forecast period (2021 to 2031).

Company Profiles:

  • Novartis AG
  • Gilead Sciences Inc.
  • Celgene Corporation
  • bluebird bio, Inc.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Key Takeaways from Market Study

  • By product, Yescarta (axicabtagene ciloleucel) holds high share of approximately 59%.
  • By indication, relapsed large B-cell lymphoma accounts for approximately 93% market share.
  • By end user, cancer treatment centers account for around 92% share in the market.
  • By region, North America holds the largest share of 68.1% of the global CAR T-cell therapy market, due to increasing number of life science companies focusing on the development and commercial manufacturing of CAR T-cells in the region.

“Increasing prevalence of cancer and continuous R&D on cell-based therapies are expected to drive demand for CAR T-cell therapy over the decade,” says a Persistence Market Research analyst.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/28264

Who is Winning in This Space?

Many of the chief players in the CAR T-cell therapy market are focusing on product launches and collaborations for global expansion.

  • In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition helps Celgene advance in cellular immunotherapy by adding novel technology and advanced cellular manufacturing capabilities to its portfolio.
  • In August 2017, Gilead Science announced the acquisition of Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
  • In March 2021, Kite Pharma gained FDA approval for axicabtagene ciloleucel (axi-cel), a CAR T-cell based therapy.

Want More Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031.

The market is segmented in detail based on product (Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), JCAR017 (lisocabtagene maraleucel), and bb2121) indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma), and end user (hospitals and cancer treatment centers), across seven major regions of the world.

About Us: - Persistence Market Research

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th Floor New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Comments

Post a Comment

Popular posts from this blog

The Metabolomics Biomarker Market to Grow Beyond Linear Progression

  The Metabolomics Biomarker Market is all set to go great guns in the forecast period. Big data makes way for real-time data visualization, thereby identifying the high-risk populations. Healthcare organizations are into sharing more data. This creation and collection of bigger datasets are likely to increase precision and help organizations in spotting trends. These trends are expected to keep the entire healthcare vertical on the toes. Metabolomics Biomarkers are used for discovery of new insights, assessment method and treatment options for pathological diseases other than the traditional ideas. Metabolites are small molecules which are responsible for cellular processes and metabolism in an organism. Metabolites are used for biomarker discovery by metabolite profiling in cells, tissues or biofluids. Biomarkers acts as indicators for response in the form of a biological process of a drug, toxin or therapy. Metabolomics biomarkers are also used to evaluate the progress of the di...
Read more

The Clinical Trial Management System Market to virtually grow beyond geographies

  The Clinical Trial Management System Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period. Persistence Market Research has recently published a  global market study on  clinical trial management systems . The market is estimated to be valued at  US$ 2 Bn  in 2021 and is expected to surge at a  CAGR of 14%  from 2021 to 2031, to reach an estimated value of  US$ 7 Bn  by the end of 2031. Clinical trial is a medical research study performed on humans to check the safety and efficacy of drugs, devices and therapeutic products before they are finally launched in the market. Globally, the CTMS market is witnessing significant growth due to i...
Read more

Customization of care to drive the Cardiovascular Information Systems Market

Image
  The Cardiovascular Information Systems Market is ascertained to make greater strides in the future. The present-day and futuristic cutting-edge technology, namely IoT, AI, and Big Data operate better in a lightning-fast and reliable internet connection. The benefits of high-speed internet would be seen in telecare in the next 2-3 years, but going forward, more authentic data streams are likely to come up with better-connected devices, thereby revolutionizing the healthcare system. As the global healthcare industry addresses a paradigm shift towards coordinate care services, medical practitioners are compelled to develop databases for structuring case studies in the future. This necessitates the need for recording essential information on prevalent disorders such as cardiovascular diseases. A latest study developed by Persistence Market Research predicts that the demand for cardiovascular information systems will keep surging in the upcoming decade. And, rising adoption of structu...
Read more